
Opinion|Videos|June 5, 2025
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety.
Advertisement
Episodes in this series

The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).
- ABLE-32 Trial: This is a phase 3, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of nadofaragene firadenovec in patients with intermediate-risk NMIBC. The study aims to assess the treatment’s ability to reduce the recurrence and progression of bladder cancer in this patient population.
- ABLE-41 Trial: This is a real-world, observational trial that investigates the use of nadofaragene firadenovec outside the controlled environment of clinical trials. The study seeks to gather data on its effectiveness and safety in routine clinical practice, providing insights into its use across a broader, more diverse patient population.
Both trials contribute to expanding the understanding of nadofaragene firadenovec as a potential treatment option for NMIBC.
Advertisement
Related to this article

Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.

Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.

The phase 1/2 ARGATE-001 trial will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer.

Expert urologists argue that testosterone is an underused biomarker of men’s health, and review how TRAVERSE resolved longstanding cardiovascular safety concerns.

Moderators in 4 forums reviewed ARANOTE, ARACOG, and ARASEC data and discussed what differentiates doublet options in mCSPC.

Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027
Advertisement
Advertisement
Trending on Urology Times
1
Rethinking Testosterone Therapy After the FDA Label Revisions
2
FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC
3
BPH treatment patterns: Understanding regional differences in baseline ED treatment
4
Gedatolisib plus darolutamide: Early findings in mCRPC
5
